Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions

Boris J Winterhoff, Stefan Kommoss, Florian Heitz, Gottfried E. Konecny, Sean C. Dowdy, Sally A Mullany, Tjoung Won Park-Simon, Klaus Baumann, Felix Hilpert, Sara Brucker, Andreas du Bois, Willibald Schröder, Alexander Burges, Steven Shen, Jinhua Wang, Roshan Tourani, Sisi Ma, Jacobus Pfisterer, Constantin Aliferis, MD, PhD

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

We report recent progress in the development of a precision test for individualized use of the VEGF-A targeting drug bevacizumab for treating ovarian cancer. We discuss the discovery model stage (i.e., past feasibility modeling and before conversion to the production test). Main results: (a) Informatics modeling plays a critical role in supporting driving clinical and health economic requirements. (b) The novel computational models support the creation of a precision test with sufficient predictivity to reduce healthcare system costs up to $30 billion over 10 years, and make the use of bevacizumab affordable without loss of length or quality of life.

Original languageEnglish (US)
Pages (from-to)1093-1102
Number of pages10
JournalAMIA ... Annual Symposium proceedings. AMIA Symposium
Volume2018
StatePublished - Jan 1 2018

Fingerprint Dive into the research topics of 'Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions'. Together they form a unique fingerprint.

Cite this